Cormark Issues Pessimistic Estimate for Cresco Labs Earnings

Cresco Labs Inc. (OTCMKTS:CRLBF) – Cormark decreased their FY2025 earnings per share estimates for shares of Cresco Labs in a report released on Monday, August 11th. Cormark analyst J. Pytlak now expects that the company will post earnings per share of ($0.14) for the year, down from their previous estimate of ($0.07). The consensus estimate for Cresco Labs’ current full-year earnings is ($0.20) per share. Cormark also issued estimates for Cresco Labs’ FY2026 earnings at ($0.06) EPS.

Separately, Canaccord Genuity Group cut Cresco Labs from a “strong-buy” rating to a “moderate buy” rating in a research report on Tuesday, June 3rd.

Cresco Labs Price Performance

OTCMKTS CRLBF opened at $1.12 on Wednesday. The company has a market capitalization of $547.49 million, a price-to-earnings ratio of -8.58 and a beta of 1.42. The company has a debt-to-equity ratio of 1.33, a quick ratio of 1.98 and a current ratio of 3.10. The stock has a 50-day moving average of $0.60 and a 200 day moving average of $0.70. Cresco Labs has a one year low of $0.43 and a one year high of $2.05.

Cresco Labs (OTCMKTS:CRLBF) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Cresco Labs had a negative return on equity of 11.77% and a negative net margin of 6.67%. The business had revenue of $163.62 million during the quarter, compared to the consensus estimate of $162.00 million.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.